8-K: Sight Sciences Secures $65 Million Credit Facility with Hercules Capital, Refinances Existing Debt

Sight Sciences has closed a new senior secured credit facility with Hercules Capital for up to $65 million, immediately drawing $35 million to refinance existing debt and enhance financial flexibility.

Summary

• Sight Sciences has entered into a loan and security agreement with Hercules Capital for a senior secured term loan facility of up to $65 million.
• An initial tranche of $35 million was funded immediately, with net proceeds of $34.6 million after deducting fees and expenses.
• The company used the initial funding to repay its previous term loan from MidCap, totaling $37.7 million including termination fees.
• The facility includes additional tranches: $5 million available until December 15, 2024, $10 million available until September 15, 2025, and $15 million available during the interest-only period, subject to lender approval.
• The term loan facility has a maturity date of July 1, 2028, and requires an exit fee of 5.95% of the originally funded term loans upon repayment.
• The interest rate is a floating annual rate based on the greater of 10.35% or the Wall Street Journal prime rate plus 2.35%, with a 3% increase upon an event of default.
• Sight Sciences will issue warrants to Hercules to purchase common stock, initially equal to 2% of the initial loan, and 2% of any future tranche loans.
• The company is required to maintain a minimum cash balance of 85% of total secured obligations, which reduces to 35% upon achieving certain performance milestones.
• The company must also maintain trailing six-month GAAP revenue equal to 80% of the board-approved revenue forecast, subject to certain cash balance and market capitalization waivers.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the new credit facility and its benefits. However, there are some risks and costs associated with the loan, which temper the overall sentiment.

Positives

• The new credit facility strengthens the company's balance sheet.
• It provides enhanced financial flexibility and extends the company's cash runway.
• The partnership with Hercules Capital is seen as a positive step for scaling the business.
• The interest-only period provides some flexibility in the short term.

Negatives

• The company had to pay $37.7 million to terminate the previous loan with MidCap.
• The loan includes a 5.95% exit fee on the originally funded term loans.
• The interest rate is a floating rate, which could increase if the prime rate rises.
• The company is subject to minimum cash and revenue covenants.

Risks

• The company is subject to minimum cash and revenue covenants, which could be challenging to meet.
• The floating interest rate could increase the cost of borrowing.
• The company is required to issue warrants to Hercules, which could dilute existing shareholders.
• The loan is secured by substantially all of the company's assets, which could be at risk in case of default.

Future Outlook

The company aims to use the new credit facility to execute its strategic plan, extend its cash runway, and scale its business over the coming years. The company also has the potential to draw an additional $30 million subject to certain conditions.

Management Comments

• Ali Bauerlein, Chief Financial Officer of Sight Sciences, stated that the new facility strengthens the balance sheet and enhances the ability to execute the strategic plan.
• Lake McGuire, Managing Director at Hercules Capital, said that the capital commitment aims to help Sight Sciences deliver on its mission to transform the treatment of eye diseases.

Industry Context

This announcement reflects a trend of life sciences and technology companies seeking customized debt financing to support growth and strategic initiatives. Hercules Capital is a well-known lender in this space, indicating a level of confidence in Sight Sciences' business model and future prospects.

Comparison to Industry Standards

• The terms of the loan, including the interest rate and maturity, are fairly standard for venture debt financings in the medtech industry.
• The inclusion of warrants is a common feature in such deals, providing the lender with potential upside if the company performs well.
• The minimum cash and revenue covenants are also typical, designed to protect the lender's investment.
• Compared to other similar companies, Sight Sciences has secured a significant amount of capital, which should provide them with a good runway for growth.
• The 5.95% exit fee is within the typical range for venture debt, but it is a significant cost to consider.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of warrants.
• Employees may benefit from the company's increased financial stability.
• Customers may see improved products and services as the company scales its business.
• Creditors may have increased confidence in the company's ability to repay its debts.
• Suppliers may benefit from increased business with the company.

Next Steps

• Sight Sciences will continue to execute its strategic plan.
• The company will work to meet the minimum cash and revenue covenants.
• The company may draw additional tranches of the loan, subject to certain conditions.
• The company will issue warrants to Hercules Capital.

Key Dates

Keywords

credit facility, term loan, Hercules Capital, debt refinancing, financial flexibility, senior secured, warrants, minimum cash, revenue covenants, medtech